Mobidiag Ltd., an Espoo, Finland-based molecular diagnostics company, completed a €4m funding round.
The round was supported by the Finnish investment service company Springvest Oy (former Kansalaisrahoitus) with participation from more than 200 investors.
The company intends to use the funds to scale up its production of Novodiag instruments and disposable cartridges, as well as to strengthen its sales and marketing activities globally.
Established in 2000 and led by Tuomas Tenkanen, CEO, Mobidiag develops and commercialises innovative solutions to advance the diagnosis of infectious diseases and serves the clinical diagnostics market since 2008. Product lines currently available include Amplidiag® and Novodiag®.
Combining Amplidiag and Novodiag solutions, the company offers a comprehensive line of products for diagnostics for infectious diseases and antibiotic resistances. Mobidiag is able to cover all laboratories requirements no matter their size, throughput and centralised/ decentralised organisation.
The company also has subsidiaries in France, UK and Sweden and R&D centers in Finland and France.